

Neoadjuvant and Adjuvant Treatment in Early-Stage NSCLC: Options Are Expanding – Clinical Brief #2

References

Tweet 2

Ahern E, Solomon BJ, Hui R, et al. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time? *J Immunother Cancer*. 2021;9:e002248. doi:10.1136/jitc-2020-002248

Glossary

CC, cubic centimeter

Chemo, chemotherapy

CI, confidence interval

CT, computed tomography

EFS, event-free survival

ECOG, Eastern Cooperative Oncology Group

EGFR, estimated glomerular filtration rate

HR, hazard ratio

ICI, immune checkpoint inhibitor

IO, immunotherapy

MPR, major pathological response

N, node

NR, no response

NSCLC, non-small cell lung cancer

OR, odds ratio

pCR, pathological complete response

PD-L1, programmed death-ligand 1

Q6W, every 6 weeks

R0, microscopically complete resection

RUL, right upper lobe

SBRT, stereotactic body radiotherapy

TPS, total performance score

w/, with

YO, years old